Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01327885
Show Display Options
Rank Status Study
1 Active, not recruiting Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Interventions: Drug: Eribulin mesylate 1.4 mg/m2 intravenous;   Drug: Dacarbazine of 850 mg/m2, or 1,000 mg/m2, or 1,200 mg/m2 IV

Indicates status has not been verified in more than two years